Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey

Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey

Abstract Background In acute lymphoblastic leukemia (ALL), the presence of minimal residual disease (MRD) after induction/consolidation chemotherapy is a strong prognostic factor for subsequent relapse and mortality. Accordingly, European clinical guidelines and protocols recommend testing patients...

Full description

Bibliographic Details
Main Authors: Arnaud Pigneux, Pau Montesinos, Ze Cong, Xinke Zhang, Anja K. Pownell, Heather Wieffer, Jan McKendrick, Monika Brüggemann
Format: Article
Language:English
Published: BMC 2018-11-01
Series:BMC Cancer
Subjects:
MRD testing
ALL
Minimal residual disease
Cross-sectional survey
Online Access:http://link.springer.com/article/10.1186/s12885-018-5002-5

Internet

http://link.springer.com/article/10.1186/s12885-018-5002-5

Similar Items